Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Tarsus Pharmaceuticals, Inc. | d94850dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 17, 2020
Tarsus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-39614 | 81-4717861 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
15440 Laguna Canyon Road, Suite 160
Irvine, California 92618
(Address of principal executive offices, including zip code)
(949) 409-9820
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| Common Stock, par value $0.0001 per share | TARS | The Nasdaq Global Market LLC (Nasdaq Global Select Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| Item 7.01. | Regulation FD Disclosure. |
On November 17, 2020, Bobak Azamian, M.D., Ph.D., the Chief Executive Officer of Tarsus Pharmaceuticals, Inc. (the “Company”) presented an overview of the Company at the Jefferies Virtual London Healthcare Conference (the “Investor Presentation”). Dr. Azamian presented on Tuesday, November 17, 2020 at 2:35 A.M. PST, the time of which was advanced from the time previously announced.
The Investor Presentation may be accessed under the “For Investors” tab on the Company’s website at www.tarsusrx.com and will be available for replay for a period of 90 days. Additionally, a copy of the slides comprising the Investor Presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit |
Description | |
| 99.1 | Tarsus Pharmaceuticals, Inc. November 17, 2020 Investor Presentation. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 17, 2020
| Tarsus Pharmaceuticals, Inc. | ||
| By: | /s/ Bobak Azamian | |
| Bobak Azamian, M.D., Ph.D. | ||
| President and Chief Executive Officer | ||